TVTX
Travere TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-05
Current thesis
The core bullish case improved materially after the April 13, 2026 FDA approval expanded FILSPARI into FSGS, giving Travere a second rare-kidney commercial leg. Primary company materials also showed strong 2025 FILSPARI momentum, with full-year U.S.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
As of May 4, 2026, no verified Q1 2026 earnings release or 8-K was found in the checked primary sources, leaving revenue/EPS surprise, guidance, and revision signals unavailable [#IR-2026-04-27].
Momentum
94
Value
49
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $43.00 · Bull $52.00 · Bear $34.00
Data freshness
Prices
As of 2026-08-05
Fundamentals
As of 2026-08-05 • Vendor: Data Vendor v1
Scores
As of 2026-08-05 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-08-05
Investment thesis
As of 2026-08-05
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $69.43
Why
Momentum94 · Δ7d +2.3
Value49 · Δ7d -0.1
Sentiment20 · Δ7d +8.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
94
10% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
-1.8
Value
49
40% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
20
49% active weight
Current posture
7d trendImproving
Δ7d
+8.3
Δ21d
+6.4
Why this grade
Composite grade F. Momentum 93.5 / Value 48.5 / Sentiment 19.6
Fundamentals (TTM)As of 2026-08-05
Fundamentals (TTM)
As of 2026-08-05
Market Cap
$5.84B
Beta
0.84
Shares Out
92.99M
P/E (TTM) · Derived
-111.4
P/S (TTM)
7.82
P/FCF (TTM) · Derived
146.53
Rev YoY
+55.6%
EPS YoY
-14.6%
Gross Margin
+84.9%
Op Margin
-20.9%
Net Debt
$5.94M
Current Ratio
3.13
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology